Perspective Therapeutics, Inc.
CATX- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000728387
In the last 90 days, Perspective Therapeutics, Inc. insiders filed 1 open-market purchase and 5 sales; 131 institutions reported holding it in 13F filings for Q2 2026, worth $297.6M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $99.7M
- Insider buysLast 90 days, $37.9K in total
- 1
- Insider sellsLast 90 days, $1.62M in total
- 5
- 13F holdersQ2 2026, −6 vs. previous quarter
- 131
- 13F valueReported value at the end of Q2 2026
- $297.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2026
- –
- No comparable prior period
- Net income, FY2026
- -$103.1M
- No comparable prior period
- Free cash flow, FY2026
- -$95.2M
- No comparable prior period
- Revenue, Q3 FY2027
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 8.97M
- Shares sold short
- Change
- −7.70M
- −46.2% vs. previous
- Days to cover
- 2.47
- At average daily volume
Superinvestors holding CATX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding CATX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Perspective Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 12, 2026 (view filing)8:30 AM ET | Nov 11 | 1 day | Spoor Johan M.Chief Executive Officer | PPurchase | +47.0K | $0.8073 | +$37.9K | +79.1%106.4K after | |
| Sep 8, 2026 (view filing)4:51 PM ET | Sep 3-4 | 5 days | Lantheus Holdings, Inc. and 1 other10% Owner | SSale | −247.9K | $3.13 | −$776.9K | −2.2%11.3M after | 2 lots |
| Sep 4, 2026 (view filing)5:00 PM ET | Sep 2 | 2 days | Lantheus Holdings, Inc. and 1 other10% Owner | SSale | −42.1K | $3.11 | −$131.2K | −0.4%11.5M after | |
| Sep 4, 2026 (view filing)4:58 PM ET | Aug 31-Sep 1 | 4 daysLate | Lantheus Alpha Therapy, LLC10% Owner | SSale | −113.9K | $3.14 | −$357.2K | −1.0%11.6M after | 2 lots |
| Sep 3, 2026 (view filing)4:54 PM ET | Sep 1 | 2 days | Lantheus Holdings, Inc.10% Owner | SSale | −35.8K | $3.12 | −$111.6K | −0.3%11.6M after | |
| Sep 2, 2026 (view filing)4:36 PM ET | Aug 31 | 2 days | Lantheus Holdings, Inc.10% Owner | SSale | −78.1K | $3.14 | −$245.6K | −0.7%11.6M after | |
| Nov 17, 2025 (view filing) | Nov 13 | 4 days | Hunt Jonathan RobertChief Accounting Officer | PPurchase | +11.0K | $2.03 | +$22.3K | +22.5%59.8K after | |
| Nov 14, 2025 (view filing) | Nov 12 | 2 days | Williamson Robert F IIIDirector | PPurchase | +9.50K | $2.10 | +$19.9K | +2,595.1%9.86K after | |
| Apr 1, 2025 (view filing) | Mar 28 | 4 days | Spoor Johan M.Chief Executive Officer | PPurchase | +22.0K | $2.24 | +$49.3K | +59.0%59.4K after | |
| Apr 1, 2025 (view filing) | Mar 28 | 4 days | Spoor Johan M.Chief Executive Officer | PPurchase | +4.65K | $2.21 | +$10.3K | New position4.65K after |
Top 10 13F holders, Q2 2026
See all 131 holdersThe largest institutional positions in Perspective Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9,494,152 | $32.4M | 0.00% | +4,145,591+77.5% | Added |
| TCG Crossover Management, LLC | 7,915,567 | $27.0M | 0.65% | 00.0% | Unchanged |
| Commodore Capital LP | 6,336,782 | $21.6M | 1.29% | 00.0% | Unchanged |
| Avidity Partners Management LP | 6,299,999 | $21.5M | 3.44% | +250,000+4.1% | Added |
| State Street Corp | 6,051,771 | $20.6M | 0.00% | +2,919,101+93.2% | Added |
| Millennium Management LLC | 4,911,855 | $16.7M | 0.01% | +865,215+21.4% | Added |
| Vanguard Capital Management LLC | 4,436,572 | $15.1M | 0.00% | +57,616+1.3% | Added |
| Affinity Asset Advisors, LLC | 4,214,582 | $14.4M | 0.70% | +1,050,000+33.2% | Added |
| Citadel Advisors LLC | 3,805,739 | $13.0M | 0.01% | +239,235+6.7% | Added |
| Spruce Street Capital LP | 3,693,931 | $12.6M | 2.47% | +1,066,824+40.6% | Added |
Holders of 5% or more of CATX
See all 8 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Perspective Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Commodore Capital LP | 13G | 9.90%11.9M shares | – | Apr 19, 20243 filings | Feb 9, 2026 | SEC |
| TCG Crossover GP II, LLC | 13G | 6.90%7.92M shares | New | Feb 6, 20261 filing | Feb 6, 2026 | SEC |
| BlackRock, Inc. | 13G | 6.80%7.78M shares | +2.20 ppfrom 4.60% | Oct 24, 20244 filings | Jul 29, 2026 | SEC |
| Qatar Investment Authority | 13G | 6.20%7.07M shares | New | Feb 5, 20261 filing | Feb 5, 2026 | SEC |
| Johnson Frances | 13G/A | 5.90%16.8M shares | – | Sep 19, 20232 filings | Feb 5, 2024 | SEC |